Gastrointestinal Stromal Tumour (GIST) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem
Expert Opin Investig Drugs. 2024 Feb 14:1-12. doi: 10.1080/13543784.2024.2318317. Online ahead of print.ABSTRACTINTRODUCTION: Approximately 90% of gastrointestinal stromal tumors (GISTs) are driven by activating mutations in receptor tyrosine-kinases KIT or PDGFRA. Despite the outstanding results of first-line imatinib in advanced GIST, resistance ultimately occurs mainly through secondary mutations in KIT/PDGFRA. Other tyrosine-kinase inhibitors (TKIs) with a broader spectrum of activity against these mutations are approved after imatinib failure. However, response rates and progression-free survival are drastically lower...
Source: Expert Opinion on Investigational Drugs - February 12, 2024 Category: Drugs & Pharmacology Authors: Carlo Mar ía Cicala Iv án Olivares-Rivas Jon Ander Aguirre-Carrillo C ésar Serrano Source Type: research

Pharmaco ‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G
This study provides a pharmaco-phosphoproteomic profile of D816V- and V560G-mutant KIT cells, which reveals novel therapeutic strategies that may be applicable to a range of cancers. (Source: Proteomics)
Source: Proteomics - February 10, 2024 Category: Biochemistry Authors: Heather C. Murray, Kasey Miller, Matthew D. Dun, Nicole M. Verrills Tags: DATASET BRIEF Source Type: research

Primary Pancreatic GIST — A-Single Centre Case Series and Systematic Review of Literature
ConclusionPancreatic GIST is a rare entity. Due to limited evidence and evolving literature, results cannot be generalised to a larger population. Larger case series with longer follow-up data are required to further understand the disease biology and long-term outcomes of pancreatic GIST. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - February 7, 2024 Category: Cancer & Oncology Source Type: research

Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
In light of the expected increase in the prevalence of diabetes mellitus due to an aging population, sedentary lifestyles, an increase in obesity, and unhealthy diets, there is a need to identify potential pharmacological agents that can heighten the risk of developing diabetes. Similarly, it is equally important to also identify those agents that show blood glucose-lowering properties. Amongst these agents are tyrosine kinase inhibitors used to treat certain types of cancers. Over the last two decades, there has been an increase in the use of targeted chemotherapy for cancers such as renal cell carcinoma, chronic leukaemi...
Source: Frontiers in Pharmacology - February 1, 2024 Category: Drugs & Pharmacology Source Type: research

Unexpected reaction of “wild-type” gastrointestinal stromal tumor to imatinib: case report and literature review
ConclusionThis unexpected response suggests that wild-type GISTs may benefit from TKIs treatment, and the potential mechanisms warrant further investigation. Additionally, true wild-type GIST may not be discerned due to current limitations of Next-Generation Sequencing(NGS). Therefore, for advanced/high-risk GIST, additional genetic analysis can be performed after negative NGS results. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research

Effects of surgical management for gastrointestinal stromal tumor patients with liver metastasis on survival outcomes
ConclusionSurgical treatment can improve the OS and CSS of patients with GIST-SLM. In addition, the combination with chemotherapy may be more favorable for the long-term survival of patients. Meanwhile, we constructed the nomograms for predicting OS and CSS at 1, 3, and 5-year, and validated them internally. Our model can contribute to clinical management and treatment strategy optimization. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research

Gastric tumours
encompass adenocarcinoma, the most common type, as well as gastrointestinal stromal tumours, neuroendocrine tumours and gastric lymphoma. They are typically difficult to diagnose early as the ‘red flag’ features of gastric cancer tend to be associated with advanced disease. As a result, survival outcomes of gastric cancer are poor, with 5-year survival in the UK currently at 20%. There have been significant breakthroughs in systemic therapy and surgical technology to increase chances of cure and improve survival. (Source: Medicine)
Source: Medicine - January 24, 2024 Category: Internal Medicine Authors: Nikhil M. Patel, Sacheen Kumar Tags: Stomach Source Type: research

Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors
Soft tissue sarcomas (STSs), including gastrointestinal stromal tumors (GISTs), are mesenchymal neoplasms with heterogeneous clinical behavior and represent broad categories comprising multiple distinct biologic entities. Multidisciplinary management of these rare tumors is critical. To date, multiple studies have outlined the importance of biological characterization of mesenchymal tumors and have identified key molecular alterations which drive tumor biology. GIST has represented a flagship for targeted therapy in solid tumors with the advent of imatinib which has revolutionized the way we treat this malignancy. Herein, ...
Source: Surgical Oncology Clinics of North America - January 17, 2024 Category: Surgery Authors: Adam M. Fontebasso, Jeffrey D. Rytlewski, Jean-Yves Blay, Rebecca A. Gladdy, Breelyn A. Wilky Source Type: research

Giant exophytic gastrointestinal stromal tumor (GIST) causing gastric outlet obstruction: case report and review of literature
We present the case of a middle-aged patient diagnosed with a giant gastric GIST, which presented for intermittent gastric outlet obstruction symptoms, and emphasize the major imagistic, histopathological, and therapeutic challenges that may be encountered. There are only several cases of gastric exophytic gastric GIST provoking intermittent gastric outlet obstruction. Tumor resection should be adapted to every patient's status, focused on en bloc extraction, with preservation of invaded organs as much as possible.PMID:38184841 | DOI:10.47162/RJME.64.4.17 (Source: Romanian Journal of Morphology and Embryology)
Source: Romanian Journal of Morphology and Embryology - January 7, 2024 Category: General Medicine Authors: Victor Mihai Sacerdo ţianu Cecil Sorin Mirea Petric ă Popa Dan Ionu ţ Gheonea Maria Camelia Foarf ă Marius Matei Daniela Larisa S ăndulescu Cristian Virgil Lungulescu Tudorel Ciurea Bogdan Silviu Ungureanu Source Type: research

Giant exophytic gastrointestinal stromal tumor (GIST) causing gastric outlet obstruction: case report and review of literature
We present the case of a middle-aged patient diagnosed with a giant gastric GIST, which presented for intermittent gastric outlet obstruction symptoms, and emphasize the major imagistic, histopathological, and therapeutic challenges that may be encountered. There are only several cases of gastric exophytic gastric GIST provoking intermittent gastric outlet obstruction. Tumor resection should be adapted to every patient's status, focused on en bloc extraction, with preservation of invaded organs as much as possible.PMID:38184841 | PMC:PMC10863695 | DOI:10.47162/RJME.64.4.17 (Source: Romanian Journal of Morphology and Embryology)
Source: Romanian Journal of Morphology and Embryology - January 7, 2024 Category: General Medicine Authors: Victor Mihai Sacerdo ţianu Cecil Sorin Mirea Petric ă Popa Dan Ionu ţ Gheonea Maria Camelia Foarf ă Marius Matei Daniela Larisa S ăndulescu Cristian Virgil Lungulescu Tudorel Ciurea Bogdan Silviu Ungureanu Source Type: research